



Supplementary Fig 1.

Il6 gene expression as assessed by qRT-PCR in BMDMs stimulated with OGD/R and LPS (20 ng/mL) as indicated. N, non-treated.

Statistical test by one-way ANOVA (n=4 and representative of 4 independent experiments, n.s. no significance, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).



F



Supplementary Fig 2.

A. Gene expression of NFE2L2 (NRF2) and NFE2L3 (NRF3) in BMDMs subject to OGD/R.

B. BMDMs were treated with OGD followed by different durations of reoxygenation. NRF1 proteins levels in cytosolic and nuclear fractions was analyzed by WB, and quantitation of NRF1 was normalized to α-Tubulin in cytoplasm and LAMIN A/C in nucleus.


C. BMDMs were treated with OGD followed by different durations of reoxygenation +/- H₂O₂ treatment during reoxygenation. Quantitation of NRF1 proteins levels in nucleus is shown versus LAMIN A/C.

D. BMDMs were treated with OGD followed by different durations of reoxygenation. NRF1 protein levels and mTORC1 signaling were assessed by WB. Quantitative data are presented as relative protein levels of bands intensities including NRF1/α-Tubulin, pS6K/S6K, pS6/S6 for the corresponding OGD/R stimulation time point.

E. BMDMs were subject to different durations of OGD followed by 1h reoxygenation. NRF1 levels and mTORC1 signaling were assessed by WB. Quantitative data are presented as relative protein levels of bands intensities respectively including NRF1/α-Tubulin, pS6K/S6K, pS6/S6.

F. BMDMs were subject to OGD/R +/- mTOR inhibitor (rapamycin, 400 nM) or S6K inhibitor (PF-4708671, 10 μM) during reoxygenation as indicated. NRF1 levels and mTORC1 signaling were assessed by WB(J). Quantitative data are presented as relative protein levels of bands intensities respectively including NRF1/α-Tubulin, pS6K/S6K, pS6/S6.




Statistical test by one-way ANOVA (n=3 and representative of 3 independent experiments, n.s. no significance).



Supplementary Fig 3.


Whole cell lysates from WT and NFE2L1^{-/-} BMDMs were assessed for levels of NRF1 by WB with quantitation, which was normalized to Tubulin-α.

Statistical test by one-way ANOVA (n=3 and representative of 3 independent experiments, n.s. no significance).




D

FUND1




BNIP3L




E

NFE2L1(NRF1) Cut&Tag GO analysis (TOP20)



NFE2L1(NRF1) Cut&Tag KEGG analysis (TOP20)



Supplementary Fig 4.

A-B. BMDMs were subject to OGD/R or not followed by RNA-seq analysis.

A. Genes up- and down- regulated by OGD/R stimulation relative to unstimulated.

B. KEGG analysis of gene upregulated by OGD/R stimulation relative to unstimulated.

C.WT and NFE2L1^{-/-} BMDMs were subject to OGD/R followed by analysis of the indicated mitophagy regulators by WB with quantitation, which was normalized to Tubulin- α .

D-E. WT and NFE2L1^{-/-} BMDMs were subject to OGD/R followed by NRF1 Cut and Tag-seq analysis.

D. Representative NRF1 tracks at the Fundc1 and Bnip3L genes displayed using IGV software.

E. GO and KEGG analysis to find enriched pathways in genes bound by NRF1 (i.e. upregulated in WT versus NFE2L1^{-/-} BMDMs).

Statistical test by one-way ANOVA (n=3 and representative of 3 independent experiments, n.s. no significance).

Primers	5' to 3'
NFE2L1 forward	ACTGCAAGATGGACGAGAACGA
NFE2L1 reverse	GAAACGTCAGCTGGGAACGTG
IL6 forward	ACAAAGCCAGAGTCCTTCAGAGAG
IL6 reverse	TTGGATGGTCTTGGTCCTTAGCCA
Psm5 forward	AATTGGCTCTGCTTCTGAGGGT
Psm5 reverse	GAAATTCTGACCAGGCTGCACC
Psm6 forward	AGGCCACTCGGTTGTTGTATGA
Psm6 reverse	AGCCACAGTAGTAACCTGCAGG
Psmb2 forward	ATGTGTTGGAGAGGCTGGAGAC
Psmb2 reverse	GATATGGGGTCCGACTCCGAAG
Psmb8 forward	TGGGGTGATGGACAGTGGTTAC
Psmb8 reverse	GCCTCTCCGTACTTGTACAGCA
Psmb9 forward	TATGGAACCATGGGAGGGATGC
Psmb9 reverse	GTGACCAGGTAGATGACACCCC
Psmb10 forward	TGTGGATGCCTGTGTGATCACT
Psmb10 reverse	GTGTGGTTCCAGGAGCAAATCG
Psmc1 forward	CTGCCGGATGAGAAGACCAAGA
Psmc1 reverse	CCAGAGAGGTATCCTTTGCCA
Psmc5 forward	CACTGGGAAGACATTGTTGGCC
Psmc5 reverse	GTTCTCGGGCCATGACAAACAG
Psmd10 forward	GGTGCACATGTGAATGCTGTCA
Psmd10 reverse	TGGTCCTTCGCATCTGGGTTAG
Psme1 forward	GGTCACTACCTGGTTGCAGCTA
Psme1 reverse	ACTTGAGATCTGCGTGTGGAA
Psme2 forward	GAGGCTGATGACTTCCTCTGCA
Psme2 reverse	GGAATCCTCCTGCAAGAGCTGA
Fundc1 forward	GTCGTGTACAGGGAAGAGTGG
Fundc1 reverse	TCTAGGCCGAGTTGGAAGTCT
Bnip3L forward	CTCAGCCCCTCCGGCTATTG
Bnip3L reverse	GTGCGGAAGTCGAGCTGATA
Actin β forward	CGGTTCCGATGCCCTGAGGCTCTT
Actin β reverse	CGTCACACTTCATGATGGAATTGA
NFE2L2 forward	CTTTAGTCAGCGACAGAAGGAC
NFE2L2 reverse	AGGCATCTTGTTTGGGAATGTG
NFE2L3 forward	TGAGCCAAGCTATAAGCCATGA
NFE2L3 reverse	AATGGTTCTTGTGCCTGTGAA

Supplementary table 1.
Primer sequences

Fig2B




Fig2C




Fig3A




Fig3D




Fig2D




Fig2F




Fig5B




Fig5D




Fig5F




Fig2E



Fig2F






Fig5J



Supplementary Fig3



Supplementary Figure full blot.